Solve M.E., a California-based nonprofit involved in research into diagnostics, treatments and cures for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), Long Covid, and other infection-associated chronic conditions and illnesses (IACCIs), on Tuesday announced Simmaron Research as the second recipient of its 2025 ME/CFS Catalyst Award.

Solve M.E. says that Simmaron will receive targeted funding to accelerate its study 'Low Dose Rapamycin in ME/CFS, Long-COVID, and Other Infection Associated Chronic Conditions'. This study hypothesises that mTOR inhibition through rapamycin may address observed findings of autophagy impairment and symptoms in a subset of patients with ME/CFS and other infection-associated chronic conditions and illnesses (IACCIs).

The Solve ME/CFS Catalyst Awards are intended to be a focused initiative to ensure that promising research does not lose momentum -- especially in the face of unpredictable federal funding cycles. These awards provide strategic support to help studies reach key milestones such as publication, translation to clinical application, or advancement to the next phase of investigation.

Solve president and CEO Emily Taylor said: "We are so proud to support this bold and rigorously designed study that not only builds on promising biological insights but also advances an already FDA-approved drug as a potential treatment. This is exactly the kind of patient-centred, translational science our community needs. Our Catalyst Award will enable Simmaron to enrol more participants and collect more samples from more time points, making real movement toward meaningful care."